Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial
Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial
复制标题
DOI：
10.1002/ejhf.1700
复制
发表时间：
2020-05-01
影响因子：
18.2
通讯作者：
Kastrup, Jens
中科院分区：
文献类型：
--
作者：
Mathiasen, Anders B.;Qayyum, Abbas A.;Kastrup, Jens
Aims本研究评估了4年的结果，心肌内注射自体骨髓间充质干细胞（MSC）在缺血性heartfailure.Methods和results患者的MSC-HF试验是一项随机，双盲，安慰剂对照试验。患者以2：1的比例随机接受心肌内注射MSC或安慰剂。主要终点是通过磁共振成像或计算机断层扫描测量的左心室收缩末期容积（LVESV）的变化。60例缺血性心力衰竭患者，年龄30-80岁，纽约心脏协会II-III级，左心室射血分数（LVEF）
Aims The study assessed 4-year outcomes of intramyocardial injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in patients with ischaemic heart failure.Methods and results The MSC-HF trial was a randomized, double-blind, placebo-controlled trial. Patients were randomized 2:1 to intramyocardial injections of MSCs or placebo. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography. Sixty patients aged 30-80 years with ischaemic heart failure, New York Heart Association class II-III, left ventricular ejection fraction (LVEF)